دورية أكاديمية
أعرض في EDS

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.

التفاصيل البيبلوغرافية
العنوان: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
المؤلفون: Ha MJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Korea., Singareeka Raghavendra A; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kettner NM; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Damodaran S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Layman RM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hunt KK; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shen Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Keyomarsi K; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
المصدر: International journal of cancer [Int J Cancer] 2022 Jun 15; Vol. 150 (12), pp. 2025-2037. Date of Electronic Publication: 2022 Mar 03.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
مواضيع طبية MeSH: Breast Neoplasms*/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Piperazines ; Protein Kinase Inhibitors/therapeutic use ; Pyridines ; Receptor, ErbB-2 ; Receptors, Estrogen
مستخلص: Cyclin-dependent-kinase-4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer (BC). The Breast Medical Oncology database at MD Anderson Cancer Center (MDACC) was analyzed to assess effectiveness of the CDK4/6i palbociclib plus ET compared to ET alone. From a total of 5402 advanced HR+ HER2- BC patients referred to MDACC between 1997 and 2020, we identified eligible patients who received palbociclib in combination with first-line (n = 778) and second-line (n = 410) ET. We further identified "control" patients who received ET alone in the first-line (n = 2452) and second-line (n = 1183) settings. Propensity score matching analysis was conducted to balance baseline demographic and clinical characteristics between palbociclib and control cohorts to assess the effect of palbociclib treatment on progression-free survival (PFS) and overall survival (OS). For propensity-matched-cohort in the first-line setting (n = 708), palbociclib group had significantly longer median PFS (17.4 vs 11.1 months; P < .0001) compared to controls. Median OS (44.3 vs 40.2 months) did not show a statistically significant benefit in the first line setting. However, in the second-line setting, with 380 propensity-matched-cohort, the palbociclib group had significantly longer PFS (10 vs 5 months, P < .0001) as well as OS (33 vs 24 months; P < .022), compared to controls. We conclude that in this single center analysis of a large cohort of metastatic HR+ HER2- BC patients, palbociclib in combination with ET was associated with improved PFS in both first-line and second-line settings and OS in the second-line setting compared to ET alone cohort.
(© 2022 UICC.)
References: Breast Cancer Res Treat. 2019 Jul;176(2):429-434. (PMID: 30895534)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Target Oncol. 2018 Feb;13(1):21-38. (PMID: 29218622)
J Clin Oncol. 2018 Nov 10;36(32):3259-3268. (PMID: 30212295)
Lancet Oncol. 2015 Jan;16(1):25-35. (PMID: 25524798)
Lancet. 2019 Jun 29;393(10191):2599-2612. (PMID: 31178152)
ESMO Open. 2018 Aug 20;3(5):e000368. (PMID: 30167331)
Cancer Chemother Rep. 1966 Mar;50(3):163-70. (PMID: 5910392)
Breast. 2018 Jun;39:131-138. (PMID: 29679849)
Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
Clin Cancer Res. 2017 Jul 1;23(13):3251-3262. (PMID: 28351928)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
JAMA Oncol. 2020 Jan 01;6(1):116-124. (PMID: 31563959)
Clin Cancer Res. 2019 Dec 15;25(24):7485-7496. (PMID: 31548345)
N Engl J Med. 2019 May 16;380(20):1929-1940. (PMID: 31091374)
Future Med Chem. 2015 Aug;7(12):1511-9. (PMID: 26306654)
N Engl J Med. 2015 Oct 22;373(17):1672-3. (PMID: 26488700)
J Natl Cancer Inst. 2014 Jan;106(1):djt337. (PMID: 24317176)
Stat Med. 1998 Oct 15;17(19):2265-81. (PMID: 9802183)
N Engl J Med. 2018 Nov 15;379(20):1926-1936. (PMID: 30345905)
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1039-45. (PMID: 25969506)
N Engl J Med. 2016 Nov 3;375(18):1738-1748. (PMID: 27717303)
J Breast Cancer. 2021 Feb;24(1):97-105. (PMID: 33634624)
Surg Clin North Am. 2003 Aug;83(4):803-19. (PMID: 12875597)
J Clin Oncol. 2013 Nov 1;31(31):3997-4013. (PMID: 24101045)
Lancet Oncol. 2018 Jul;19(7):904-915. (PMID: 29804902)
N Engl J Med. 2019 Jul 25;381(4):307-316. (PMID: 31166679)
Ther Adv Med Oncol. 2021 Mar 10;13:1758835920987651. (PMID: 33796150)
N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498)
Breast Cancer Res Treat. 2020 Sep;183(2):419-428. (PMID: 32683565)
JAMA. 2018 Sep 4;320(9):867-868. (PMID: 30105359)
Multivariate Behav Res. 2011 May;46(3):399-424. (PMID: 21818162)
J Nucl Cardiol. 2019 Apr;26(2):391-393. (PMID: 30719655)
Lancet Oncol. 2016 Apr;17(4):425-439. (PMID: 26947331)
N Engl J Med. 2020 Feb 6;382(6):514-524. (PMID: 31826360)
N Engl J Med. 2016 Nov 17;375(20):1925-1936. (PMID: 27959613)
Mol Cancer Ther. 2004 Nov;3(11):1427-38. (PMID: 15542782)
N Engl J Med. 2015 Jul 16;373(3):209-19. (PMID: 26030518)
Breast Cancer Res. 2021 Mar 24;23(1):37. (PMID: 33761995)
Ann Oncol. 2018 Jul 1;29(7):1541-1547. (PMID: 29718092)
J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. (PMID: 16813731)
N Engl J Med. 2012 Feb 9;366(6):520-9. (PMID: 22149876)
NPJ Breast Cancer. 2019 Jan 17;5:5. (PMID: 30675515)
Clin Cancer Res. 2020 Oct 1;26(19):5172-5177. (PMID: 32546646)
J Natl Cancer Inst. 2014 Apr 28;106(5):. (PMID: 24777111)
P T. 2008 Dec;33(12):700-11. (PMID: 19750051)
J Clin Oncol. 2010 Jun 1;28(16):2784-95. (PMID: 20404251)
J Clin Oncol. 2018 Aug 20;36(24):2465-2472. (PMID: 29860922)
Breast Cancer (Auckl). 2019 Jan 10;13:1178223418823238. (PMID: 30675102)
Breast Cancer Res. 2016 Jun 28;18(1):67. (PMID: 27349747)
J Clin Oncol. 2017 Sep 1;35(25):2875-2884. (PMID: 28580882)
J Natl Compr Canc Netw. 2019 Feb;17(2):141-147. (PMID: 30787127)
معلومات مُعتمدة: P30 CA016672 United States CA NCI NIH HHS; R01 CA223772 United States CA NCI NIH HHS; R01 CA255960 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: CDK4/6 inhibitors; Propensity matching; aromatase inhibitors; endocrine therapy; fulvestrant; hormone receptor; metastatic breast cancer; overall survival; progression-free survival
المشرفين على المادة: 0 (Piperazines)
0 (Protein Kinase Inhibitors)
0 (Pyridines)
0 (Receptors, Estrogen)
EC 2.7.10.1 (Receptor, ErbB-2)
G9ZF61LE7G (palbociclib)
تواريخ الأحداث: Date Created: 20220208 Date Completed: 20220419 Latest Revision: 20230616
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9018572
DOI: 10.1002/ijc.33959
PMID: 35133007
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0215
DOI:10.1002/ijc.33959